ESTRO 2024 - Abstract Book

S1621

Clinical - Lung

ESTRO 2024

Figure 1. Progression-free survival (A-C) and overall survival (B-D) according to tumor irradiation fractionation, without (A-B) or with (C-D) propensity score matching

Conclusion:

In eligible LA-NSCLC patients, SBRT can be an effective and safe treatment. Multicenter studies should be performed to evaluate the best regimen, the immunomodulatory effect of this treatment, and identify patients who benefit most of this fractionation.

Keywords: LA-NSCLC, SBRT, Durvalumab

References: